Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994810 | 0.87 | HTT (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL4707514 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL14711335 | 0.76 | POLB (0.57) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3032322 | 0.76 | ALDH1A1 (0.53) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8800218 | 0.76 | BRD4 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL768777 | 0.75 | PTGS1 (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL5750757 | 0.75 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL5209802 | 0.75 | ALDH1A1 (0.52) | ALDH1A1NPSR1SMN1; SMN2HTTMAPT | |
| SCHEMBL3036700 | 0.75 | HTT (0.56) | ALDH1A1NPSR1NPC1SMN1; SMN2ELANE | |
| SCHEMBL3033421 | 0.74 | HTT (0.58) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| EP-1781621-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
| WO-2005123693-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE4B | ALDH1A1 324/4885CYP3A4 17/4885CYP2C9 147/4885 |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | ALDH1A1 525/4885CYP3A4 38/4885CYP2C9 314/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | ALDH1A1 525/4885CYP3A4 38/4885CYP2C9 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.